Last reviewed · How we verify

NCT05525364: DIAB-ONCO

Hyperglycaemia In Childhood Hematologic Malignancies

Completed Last updated 1 September 2022
What this trial tests

trial in Diabetes Mellitus Risk in 303 participants. Completed in 31 August 2020.

Timeline
20 June 2019
Primary endpoint
31 August 2020
31 August 2020

Quick facts

Lead sponsorUniversité Catholique de Louvain
StatusCompleted
Study typeOBSERVATIONAL
Enrollment303
Start date20 June 2019
Primary completion31 August 2020
Estimated completion31 August 2020
Sites1 location across Belgium

Conditions studied

Sponsor

Université Catholique de Louvain — full company profile →

Who can join

Adults 0 to 18, any sex, with Diabetes Mellitus Risk. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

BACKGROUND/AIM: Secondary forms of diabetes are often understudied and underdiagnosed in children and adolescents with cancer. The objectives of this cohort study were to study the incidence and risk factors for hyperglycaemia in leukaemia and lymphoma patients. METHODS: The investigators retrospectively collected 15 years of data from paediatric patients treated for acute lymphoblastic leukaemia (ALL), Hodgkin's lymphoma (HL), and non-Hodgkin's lymphoma (NHL) immediately at cancer diagnosis. They studied risk factors for hyperglycaemia in univariate and multivariate analyses.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Diabetes Mellitus Risk

Currently open trials in the same condition.

Other Université Catholique de Louvain trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05525364.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing